The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

POU6F1  -  POU class 6 homeobox 1

Homo sapiens

Synonyms: BRN5, Brain-5, Brain-specific homeobox/POU domain protein 5, Brn-5, MPOU, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of POU6F1


High impact information on POU6F1


Chemical compound and disease context of POU6F1

  • Intraperitoneal application of vinconate (100 and 300 mg/kg) 10 min and pentobarbital (40 mg/kg) 30 min before ischemia showed a mild reduction in the [3H]CHA binding in the brain 5 h after ischemia [9].

Biological context of POU6F1

  • Here we identify novel DNA binding sites for the POU protein mPOU (POU6F1) [10].
  • A potential function of Brn-5 may be to suppress the action of proliferative signals in postmitotic neurons and thus prevents them from reentering the cell cycle [11].
  • This 5' region was obtained via PCR methods using a human brain 5' RACE-Ready cDNA library [12].
  • We also documented seasonal variations in brain serotonergic function by our finding of reduced brain 5-HTT availability in winter (compared to summer) in healthy controls [13].

Associations of POU6F1 with chemical compounds


Other interactions of POU6F1


Analytical, diagnostic and therapeutic context of POU6F1

  • We assessed brain 5-HT1A receptor binding potential directly using the specific radioligand [11C]WAY-100635 and positron emission tomography (PET) [1].
  • No FBM metabolites were detected in brain 5 min after administration: In silica gel thin-layer chromatography (TLC), a single [14C]FBM peak was detected--Rf = 0.504 (70:30 acetone:hexane) [18].
  • This lesion did not demonstrate significant changes in the vasculature but did have radiation necrosis of the surrounding brain 5 years after 25 Gy equivalents of helium-ion radiosurgery [19].


  1. Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635. Cleare, A.J., Messa, C., Rabiner, E.A., Grasby, P.M. Biol. Psychiatry (2005) [Pubmed]
  2. Effects of vinconate and pentobarbital against postischemic alterations in spirodecanone binding sites in the gerbil brain. Murakami, F., Araki, T., Kanai, Y., Kato, H., Fujiwara, T., Kogure, K. Pharmacology (1994) [Pubmed]
  3. Critique for: Di Rocco, c.; Di Trapani, G.; Pettorossi, V.E., and Caldarelli, M: On the pathology of experimental hydrocephalus induced by artificial increase in endoventricular CSF pulse pressure. Child's Brain 5: 81--95 (1979). McLone, D.G. Child's brain. (1979) [Pubmed]
  4. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Turecki, G., Brière, R., Dewar, K., Antonetti, T., Lesage, A.D., Séguin, M., Chawky, N., Vanier, C., Alda, M., Joober, R., Benkelfat, C., Rouleau, G.A. The American journal of psychiatry. (1999) [Pubmed]
  5. Primary structure of the serotonin transporter in unipolar depression and bipolar disorder. Lesch, K.P., Gross, J., Franzek, E., Wolozin, B.L., Riederer, P., Murphy, D.L. Biol. Psychiatry (1995) [Pubmed]
  6. Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats. Pentel, P.R., Dufek, M.B., Roiko, S.A., Lesage, M.G., Keyler, D.E. J. Pharmacol. Exp. Ther. (2006) [Pubmed]
  7. Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study. Kanerva, H., Vilkman, H., Någren, K., Kilkku, O., Kuoppamäki, M., Syvälahti, E., Hietala, J. Psychopharmacology (Berl.) (1999) [Pubmed]
  8. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Newman-Tancredi, A., Assié, M.B., Leduc, N., Ormière, A.M., Danty, N., Cosi, C. Int. J. Neuropsychopharmacol. (2005) [Pubmed]
  9. Postischemic alteration of muscarinic acetylcholine and adenosine A1 binding sites in gerbil brain. Protective effects of a novel vinca alkaloid derivative, vinconate, and pentobarbital using an autoradiographic study. Araki, T., Kato, H., Kogure, K. Research in experimental medicine. Zeitschrift für die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie. (1992) [Pubmed]
  10. Identification of novel DNA binding sites recognized by the transcription factor mPOU (POU6F1). Wey, E., Schäfer, B.W. Biochem. Biophys. Res. Commun. (1996) [Pubmed]
  11. Expression of the POU transcription factor Brn-5 inhibits proliferation of NG108-15 cells. Cui, H., Bulleit, R.F. Biochem. Biophys. Res. Commun. (1997) [Pubmed]
  12. Genomic organization, cDNA sequence, bacterial expression, and purification of human seryl-tRNA synthase. Vincent, C., Tarbouriech, N., Härtlein, M. Eur. J. Biochem. (1997) [Pubmed]
  13. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology. Kasper, S., Tauscher, J., Willeit, M., Stamenkovic, M., Neumeister, A., Küfferle, B., Barnas, C., Stastny, J., Praschak-Rieder, N., Pezawas, L., de Zwaan, M., Quiner, S., Pirker, W., Asenbaum, S., Podreka, I., Brücke, T. World J. Biol. Psychiatry (2002) [Pubmed]
  14. Synthesis of a [6-pyridinyl-18F]-labelled fluoro derivative of WAY-100635 as a candidate radioligand for brain 5-HT1A receptor imaging with PET. Karramkam, M., Hinnen, F., Berrehouma, M., Hlavacek, C., Vaufrey, F., Halldin, C., McCarron, J.A., Pike, V.W., Dollé, F. Bioorg. Med. Chem. (2003) [Pubmed]
  15. Effects of hydrocortisone on brain 5-HT function and sleep. Young, A.H., Sharpley, A.L., Campling, G.M., Hockney, R.A., Cowen, P.J. Journal of affective disorders. (1994) [Pubmed]
  16. Characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635--explanation of high signal contrast in PET and an aid to biomathematical modelling. Osman, S., Lundkvist, C., Pike, V.W., Halldin, C., McCarron, J.A., Swahn, C.G., Farde, L., Ginovart, N., Luthra, S.K., Gunn, R.N., Bench, C.J., Sargent, P.A., Grasby, P.M. Nucl. Med. Biol. (1998) [Pubmed]
  17. A positron emission tomography study of the effects of treatment with valproate on brain 5-HT2A receptors in acute mania. Yatham, L.N., Liddle, P.F., Lam, R.W., Adam, M.J., Solomons, K., Chinnapalli, M., Ruth, T.J. Bipolar disorders. (2005) [Pubmed]
  18. Blood-brain barrier penetration of felbamate. Cornford, E.M., Young, D., Paxton, J.W., Sofia, R.D. Epilepsia (1992) [Pubmed]
  19. Pathological changes in surgically resected angiographically occult vascular malformations after radiation. Gewirtz, R.J., Steinberg, G.K., Crowley, R., Levy, R.P. Neurosurgery (1998) [Pubmed]
WikiGenes - Universities